NCT04457687Available不适用
Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- Eisai Inc.
- 试验地点
- 22
研究概览
简要总结
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician)
- •Male or female, age at least 2 years at the time of informed consent
- •Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304
- •Has a clinical benefit from lorcaserin in the opinion of the treating physician
排除标准
- 未提供
研究者
研究点 (22)
Loading locations...
相似试验
Approved For Marketing
不适用
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Primary HyperoxaluriaNCT04125472Alnylam Pharmaceuticals
已完成
2 期
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaLymphoma, Mantle-CellNCT05564052Janssen Research & Development, LLC36
Approved For Marketing
不适用
Olaratumab (LY3012207) Patient Access for Soft Tissue SarcomaSoft Tissue SarcomaNCT03994627Eli Lilly and Company
已完成
不适用
Continued Access to the Recell® Device for Treatment of Acute Burn InjuriesBurnsNCT03333941Avita Medical76
招募中
3 期
Open Label Extension of TUDCA-ALS StudyAmyotrophic Lateral SclerosisNCT05753852Humanitas Mirasole SpA184